Hepatitis B in HIV Patients. Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center
|
|
- Reginald Kennedy
- 6 years ago
- Views:
Transcription
1 Hepatitis B in HIV Patients Mamta K. Jain, M.D., M.P.H. UT Southwestern Medical Center
2 Learning Objectives Identify tests to diagnoses HBV active infection, resolved infection, and need for immunization monitor HBV infection during treatment. What are problem(s) with routine HBV vaccinations and methods to overcome it. Identify three different oral agents for HBV treatment and resistance Be able to recognize HBV IRIS and its complications
3 Geographic Distribution of Chronic HBV Infection HBsAg Prevalence 8% - High 2-7% - Intermediate <2% - Low
4 Risk Factors for Acute Hepatitis B United States, Heterosexual* (41%) Injecting Drug Use (15%) Homosexual Activity (9%) Household Contact (2%) Health Care Employment (1%) Unknown (31%) Other (1%) * Includes sexual contact with acute cases, carriers, and multiple partners. Source: CDC Sentinel Counties Study of Viral Hepatitis
5 Acute vs. Chronic Acute Acquire as adult Clear infection/symptomatic Mode of transmission more likely horizontal 15% will become chronic More likely not to resolve infection if HIV+ Chronic Acquire in childhood Asymptomatic; unable to clear infection Mode of transmission more likely vertical
6 Worldwide Chronic HBV Epidemiology 350 million persons chronically infected 9th leading cause of death United States 847, 000 persons living with chronic hepatitis B 14,000 deaths per year attributable to hepatitis B 2 out 3 people with hepatitis B unaware about HBV 70% of HBV is in foreign-born with prevalence in foreign-born being 3-5% Other high risk populations: MSM, IDU, household contacts of HBV infected Hoofnagle N Engl J Med Abara Ann Intern Med 2017
7 HBV Diagnosis? Select the test which indicates HBV infection? A. HB core Ag (HBcAg) B. HB Surface Ag (HBsAg) C. HB Surface Ab (anti-hbs) D. HB core Ab (anti-hbc)
8 HBV Diagnosis? Select the test which indicates HBV infection? A. HB core Ag (HBcAg) B. HB Surface Ag (HBsAg) C. HB Surface Ab (anti-hbs) D. HB core Ab (anti-hbc)
9 HBV Diagnosis Select the test which indicates exposure to HBV? A. HB core Ag (HBcAg) B. HB Surface Ag (HBsAg) C. HB Surface Ab (anti-hbs) D. HB core Ab (anti-hbc)
10 HBV Diagnosis Select the test which indicates exposure to HBV? A. HB core Ag (HBcAg) B. HB Surface Ag (HBsAg) C. HB Surface Ab (anti-hbs) D. HB core Ab (anti-hbc)
11 HBV Diagnosis Select the test which indicates immunity to HBV? A. HB core Ag (HBcAg) B. HB Surface Ag (HBsAg) C. HB Surface Ab (anti-hbs) D. HB core Ab (anti-hbc)
12 HBV Diagnosis Select the test which indicates immunity to HBV? A. HB core Ag (HBcAg) B. HB Surface Ag (HBsAg) C. HB Surface Ab (anti-hbs) D. HB core Ab (anti-hbc)
13 AASLD Guidelines: Interpreting HBV Serology HBsAg Anti-HBs Total Anti-HBc IgM Anti-HBc Indicates that the person is infected Indicates recovery and immunity from HBV infection Develops in a person who has been successfully vaccinated against hepatitis B Indicates previous or ongoing infection with HBV in an undefined time frame Appears at the onset of symptoms in acute hepatitis B and persists for life Indicates recent infection with HBV ( 6 mos) This test is used to distinguish acute from chronic HBV infection CDC. Hepatitis B information for health professionals: FAQs. January 2012.
14 CDC. Hepatitis B information for health professionals: FAQs. January Interpreting HBV Serologies
15 4 Phases of Chronic HBV ALT activity Infection Current Understanding of HBV Infection HBeAg Anti-HBe HBV DNA Phase Immune Tolerant Immune Clearance Inactive Carrier State Reactivation Liver Minimal inflammation and fibrosis Chronic active inflammation Mild hepatitis and minimal fibrosis Active inflammation Yim HJ, et al. Hepatology. 2006;43:S173-S181. Copyright John Wiley & Sons, Inc. All Rights Reserved. Optimal treatment times
16 Chronic Hepatitis B Disease States HBeAg positive Also known as wild type Negative for antibody to HBeAg (anti-hbe) HBV DNA generally > 20,000 IU/mL (> 10 5 copies/ml) HBeAg negative Also known as precore mutant Positive for antibody to HBeAg (anti-hbe) HBV DNA generally > 2000 IU/mL (> 10 4 copies/ml) Keeffe EB, et al. Clin Gastroenterol Hepatol. 2008;6: Chu CJ, et al. Gastroenterology. 2003;125: Lok AS, et al. Hepatology. 2001;34;
17 What Is an Elevated ALT Level? Increased levels of the ALT enzyme can indicate liver damage Reference ranges for normal ALT vary between 2 most widely used commercial laboratories Men: 4-60 IU/L; women: 6-40 IU/L Men: 0-55 IU/L; women: 0-40 IU/L Most HBV treatment algorithms recommend lower ULN levels for ALT when making treatment-initiation decisions 30 IU/L for men 19 IU/L for women Prati D, et al. Ann Intern Med. 2002;137:1-10. Keeffe EB, et al. Clin Gastroenterol Hepatol. 2008;6: AASLD practice guidelines: chronic hepatitis B. September 2009.
18 HBV DNA Testing Indicates chronic hepatitis B when HBV DNA is still positive 6 months after acute HBV infection Can differentiate among different states of infection Change in HBV DNA level used to monitor response to therapy Increasing HBV DNA level during antiviral therapy indicates emergence of drug resistance Adapted from Keeffe EB, et al. Clin Gastroenterol Hepatol. 2008;6:
19 HBV Genotype HBV Classified into 7 genotypes A: North America and Western Europe B and C: Asia D: Southern Europe and India E: Africa F: South America G: US, HIV+ H: Central America HBV Geno B associated with less active and slowly progressive disease compared to Geno C. Non-A genotypes with poor response to nucleosides?
20 Datta, S. Virology Journal. 2008; 5:156 HBV Genotype Distribution
21 HBV:Natural History Rate of progression to cirrhosis and hepatocellular carcinoma vary State of immune system Age of patient Serologic stage of infection Geographic and genetic factors Prognostic factors for development of cirrhosis HBeAg+, Older age, Elevated ALT levels Lee N Engl J Med 1997 Lok Hepatology 2001
22 HBV: Natural History 15-40% with chronic HBV will develop cirrhosis, HCC, or liver failure 25% die prematurely due these complications Compensated cirrhosis 5 yr survival: 84% 10 yr survival: 68% Decompensated cirrhosis 5 yr survival: 14% Abara Ann Intern Med 2017
23 HBV: Natural History Spontaneous seroconversion 5% to 12% per year Case reports of spontaneous seroconversion after initiation of HAART have been reported in HIVinfected patients Perrillo Gastroenterol Clin North Am 1994 Hoofnagle Ann Intern Med 1981 Proia Am J Med 2000 Carr Lancet 1997
24 HBV/HIV: Clinical Features HBV DNA (viral load) Liver function test Liver histology higher lower less disease
25 MACS Cohort: HBV Mortality 5293 MSM 326 (6%) HBsAg+ 213 (65%)- HIV HBsAg (47%)- HIV+ Thio et al. Lancet :
26 MACS Cohort: HBV Mortality Liver Related Mortality 1.1/1000 person years HIV/HBsAg+: 14.2/1000 person years HIV+: 1.7/1000 person years (p<0.01) HBsAg+: 0.8/1000 person years (p<0.001) Highest risk of liver-related mortality CD4 nadir Relative risk (95%CI) > ( ) ( ) < ( ) Study Period Before ( ) ( ) Thio et al. Lancet :
27 HIV/HBV Mortality Metaanalysis Nikolopoulos et al. CID :
28 HBV Negatively Impacts HIV Outcomes in HIV Serconverters 2352 HIV serconverteres 20% had resolved HBV 3% isolated HBcAb 3% chronic HBV Multivariable Analysis for AIDS/death Chronic HBV vs. HBV negative HR 1.8 (95% CI ) Resolved HBV vs. HBV negative HR 1.17 (95% CI ) Isolated HBcAb vs. HBV negative HR 1.14 (95% CI ) Chun J Infect Dis 2012;205:185-93
29 HCC Leading cause of death in HIV/HBV Even with suppressed HBV DNA Need to stage liver disease Pt may have cirrhosis or advanced liver disease and you may not know it
30 Relationship Between HBV DNA and HCC Development REVEAL: long-term (mean follow-up: 11.4 yrs) cohort study to determine risk of cirrhosis and HCC among untreated HBsAg+ individuals in Taiwan Cumulative Incidence of HCC (%) 14 N = 3653 Taiwanese patients 12 Baseline HBV DNA Level, copies/ml 10 1 million 100, , ,000-99, < Yrs of Follow-up Chen CJ, et al. JAMA. 2006;295:65-73.
31 Low Adherence to HCC Screening Among HIV Providers Examined 144 HIV/HBV and 225 HBV monoinfected seen minimum 2 times over 2 years 36% of HIV/HBV in HIV practices had HCC screening 81.8% HBV monoinfected obtain HCC screening (p< ) HIV providers less frequently monitored HBV viral loads (p<.0001) HBeAg/HBeAb (p<.00001) HBsAg/anti-HBS (p<.00001) But screened more for Hep A immunity (p=0.028) Self-reported adherence and knowledge scores were the same (19 HIV providers and 16 hepatologist) Hearn Clin Infect Dis 2015;61:
32 Occult HBV Defined HBsAg-negative, anti-hbcore+ HBV DNA detectable with very sensitive assays Prevalence reported <1-15%? Higher prevalence in HIV/HCV co-infected 3030 HIV-infected, 2.5% Clinical significance? No increased risk of transaminitis due to ART Liver histology similar to those without occult HBV Palacios. HIV Clin Trials 2008;337-40
33 Hepatitis B and HCV Treatment with DAA FDA Black Box Warning Reactivation of hepatitis B seen in patients with HBV/HCV who were treated with DAA. 24 cases with confirmed reactivation of HBV Occurred within 4-8 weeks of starting treatment 3 patients decompensated; 2 died and 1 had liver transplant 12 of 24 cases received HBV treatment 5 were delayed and 1 patient died 4 pts were HBsAg+ undetectable HBV DNA 3 patients HBsAg- and undetectable HBV DNA 10 patients HBsAg status was not known
34
35 Prevention of Hepatitis B
36 Hepatitis B Vaccination Most effective measure to prevent hepatitis B 90% healthy adults are protected with a complete series Immunity lasts > 3 decades Abara Ann Intern Med 2017
37 Comparison of Standard vs. Double Dose or recombinant HBV vaccine dose Number schedule Anti-Hbs >10mIU/mL 20 μg 94 0,1,6 months 40 μg 98 0, 1, 6 monts 34% 47% P=0.07 *Those with CD4 >350 cells/μl had significantly higher rates of response (64% vs. 39%, p=0.01) **No difference occurred in those with CD4 <350 cells/μl Fonseca Vaccine 2005; 23:
38 HBV Vaccine Response in HIV patients Intervention CD4 >200 recombinant vaccine A (n=145) recombinant vaccine B (n=148) Dose Schedule route Response at 28 weeks ; Response (95% CI) 20μg 0, 4, 24 weeks 40μg 0, 4, 8, 24 weeks IM 65% (56-72% IM 82% (77-88%)* recombinant vaccine C (n=144) 4μg 0, 4, 8,24 weeks interdermal 77% (69-84%)** * p<.001 ( A vs B) ** p=0.02 (A vs. C) Launay JAMA 2011; 305:
39 New HBV Vaccination Guidelines All immunosuppressed patients HBV vaccine 40 mcg 3 doses at 0, 1, and 6 months (Recombivax) Or 4 doses of 40 mcg at 0, 1, 2, and 6 months (Engerix-B) Check anti-hbs 1 month after completion of series
40 Vaccination Against Anti-HBc Ab 54 patients Given 1 dose 20μg of recombinant HBV vaccine Those with anti-hbs <10mIU/ml at 4 weeks received 3 additional double dose (40 μg at 5, 9, 24 weeks) At wk 4, 46% were responders Non-responders at wk 4 who received further vaccination: 89% had anti-hbs 10mIU/mL at 28 weeks Piroth J Infect Dis 2016;213:
41 Strategies to Increase HBV Vaccination Response reduction in HIV viral load Increase in CD4 cell count Make sure pts receive 3 or more doses Re-vaccinate those who are initial nonresponders to vaccination series No trials to show that double dose increases response rates in prior nonresponders Whitaker Lancet Infect Dis 2012; 12: Okulicz Plos One 2014; 9: e105591
42 Prevention of HBV with ART in MSM Incident Hepatitis B Virus Infection in HIV-Infected and HIV-Uninfected Men Who Have Sex With Men From Pre-HAART to HAART PeriodsA Cohort StudyA Cohort Study Falade- Nwulia et al. Ann Intern Med. 2015;163(9):
43 HBV active ART To Prevent Incident HBV Hazard ratios (HRs) of the different factors influencing hepatitis B virus (HBV) incidence. Shilaih et al. J Infect Dis. 2016;214:
44 Treatment of HBV
45 FDA-Approved HBV Therapies Peginterferon alfa-2a Lamivudine Entecavir Tenofovir Interferon alfa-2b Adefovir Telbivudine
46 Goals of Treatment HBV DNA suppression Decreased risk of HCC Decreased progression to ESLD HBeAg+: HBeAg seroconversion HBeAg-: HBsAg loss HBsAg loss (ultimate goal)
47 HBV Treatment: Interferon Long term follow up limited Delayed clearance of HBsAg: 12-65% within 5 yrs Lower incidence of HCC and higher survival rate HBeAg-: 20% cleared HBsAg in 5 yr f/u Reduced risk HCC and liver deaths Lok Hepatology 2001
48 HBV/HIV: YMDD Resistance Author, yr Resistance Time Interval Comments Pillay, % Est. 1 yr CAESAR subanalysis Benhamou, %; Annual incidence of 20% After 2 years Resistance only in HBeAg carriers
49 Treatment of HBV in HIV- Infected Treatment Log Reduction HBeAg Seronversion Resistance (YMDD) Lamivudine 2.7 log 22-29% Tenofovir 3-5 log 25% 14-38% at 1 yr 50% at 2 yr Active against YMDD; 1 reported case Emtricitabine 2.92 log* 33%* Combination pills: Combivir (lamivudine and zidovudine) Trizivir (lamivudine, abacavir, and zidovudine) Truvada (tenofovir and emtricitabine) Atripla (efavirenz, tenofovir, and emtricitabine) Dore. J Infect Dis 1999; 180: Hoff. Clin Infect Dis 2001; 32:963-9 Pillay. AIDS 2000;14: % at 48 weeks* 18% at 96 weeks* * Data not available in HIV/HBV Benhamou. N Engl J Med 2003;348:177-8 Sheldon. Antivr Ther 2005;10: Gish. Arch Int Med 2006;166:49-56
50 Complications During Therapy
51 Acute Flares in Chronic HBV Spontaneous reactivation of chronic HBV Reactivated hepatitis due to immunosuppressive medications Cancer chemotherapy Antirejection drugs Corticosteroids Resulting from antiviral therapy Interferon Nucleoside analogues Corticosteroid withdrawal Induced by HBV genotypic variation Precore mutant Core promoter mutant HBV DNA polymerase mutant Due to superimposed infection with other hepatotropic viruses Hepatitis A,C,delta viruses Caused by interaction with HIV infection Reactivated hepatitis Effect of immune reconstitution therapy Perrillo Gastroenterology 2001
52 Acute Flare Withdrawal of HBV treatment Never stop lamivudine/emtricitabine/tenofovir in pt with HBV if you are changing HIV regimen due to HIV resistance.
53 Hepatitis B IRIS ALT (I/U) CD4 Count baseline 1mo 2mo 3mo 5mo 0 Jain et al., AIDS Patient Care & STDs, 2006
54 Elevation of Transaminases Drug-Induced Hepatotoxicity ALT increase 3-12 weeks after initiation of meds High likelihood for hepatotoxicity i.e. Nevarapine Hep B core IgM negative HBe Ag serconversion not seen Rash and fever may be seen Immune Reconstitution/HBV flare Increase in CD4 Decrease in HIV VL ALT increase 6-12 weeks after initiation of meds Hep B core IgM often positive HBeAg seroconversion may be seen during or following flare
55 Mutations HBeAg-negative variants occur naturally (HBV DNA +) Precore stop codon G1896A Basal core promoter A1762T/G1764A Mutations abolish or decrease HBeAg production
56 Entecavir Activity Against HIV On entecavir // 4 Wild type HIV M184V HIV 3.5 log HIV viral load Oct- 04 Dec- 04 Feb- 05 Apr- 05 Jun- 05 Aug- 05 Oct- 05 Dec- 05 Feb- 06 Apr- 06 Jun- 06 Aug- 06 Oct- 06 Dec- 06 Feb- 07 Jain and Zoellner AIDS, 2007
57 Resistance Nucleos(t)ide therapy and potential mutations in RT polymerase gene Drug RT Polymerase mutation lamivudine, telbivudine, emtricitabine rtm204v/i+rtl180m; rtv173l adefovir entecavir rta181v; rtn236t rtm204v+rt180m plus rt184a/c/f/g/i/l/m/s or rts202c/g/i or rtm250v/l rtm204i plus rt184i/s or rtm250i/l
58 Monitoring During HBV Treatment
59 Evaluation of HBV We asked how well do HIV providers evaluate and monitor HBV in HIV/HBV patients? To evaluate response to HBV therapy, measurement of HBV DNA is need at baseline and then during therapy.
60 HIV/HBV Patients Initiating HAART Baseline Characteristics (n=155) N (%) CD4 (cells/μl), median [range] 137 [1-1089] CD4<200 cells/μl 90 (58) Log HIV viral load (copies/ml), median [range] 4.81 [ ] ALT (IU/L), median [range] 34 [6-481] AST (IU/L), median [range] 37 [13-389] Jain. Clin Infect Dis 2007
61 Active HBV Therapy HBV Therapy N (%) Any active HBV therapy 142 (92) Lamivudine 137 (88) Tenofovir 18 (12) Emtricitabine 2 (1) Adefovir 1 (<1) Jain. Clin Infect Dis 2007
62 Monitoring of HBV in HIV/HBV Patients Testing for HBV or HIV prior to starting HAART HIV RNA prior to HAART 99% HBV DNA prior to HAART 16% Monitoring of HIV and HBV during the first year of HAART HIV RNA 1 st year of Rx 497 (median 3/pt) HBV DNA 1 st year of Rx 85 (median <1/pt) Jain. Clin Infect Dis 2007
63 HBV Tests vs. HIV Tests HBV testing HIV viral load testing HBV Tests: HBV DNA or HBeAg/anti-HBe HIV Tests: HIV RNA Jain. Clin Infect Dis 2007
64 HIV vs. HBV Kinetics HIV viral load becomes undetectable in 2-8 weeks HBV viral load may take >6 months Much higher baseline HBV DNA level
65 Management of Hepatitis B HIV/HBSAg+ to begin ART: Hepatitis B DNA quantify HBV viral load prior to initiation of ART Hepatitis B e Antigen indicates ongoing viral replication and can be used as a marker of active disease Hepatitis B e Antibody will become positive when patient has seroconverted Ultrasound of liver Cirrhosis and HCC Consider Liver biopsy to stage disease
66 Management of HBV Confirm HBV viremia Start HAART Truvada should be used as back-bone If tenofovir can not be used then entecavir should be added to ART regimen Stage Liver Disease US Fibroscan Liver biposy Fibrasure/APRI/FIB-4
67 Management of HBV Monitor HBV DNA Every 3-4 months Once HBV DNA suppressed Check HBeAg to determine if seroconversion has occurred Monitor for HCC Ultrasound and AFP yearly If cirrhotic then every 6 months
Chronic Hepatitis B: management update.
Chronic Hepatitis B: management update. E.O.Ogutu Department of clinical medicine & therapeutics, University of Nairobi. Physicians meeting,kisumu 2011. Background epidemiology Chronic hepatitis B (CHB)
More informationProfessor Vincent Soriano
Five Nations Conference on HIV and Hepatitis in partnership with Professor Vincent Soriano Hospital Carlos III, Madrid, Spain Professor Vincent Soriano in partnership with Hospital Carlos III, Madrid,
More informationAcute Hepatitis B Virus Infection with Recovery
Hepatitis B: Clear as Mud Melissa Osborn, MD, MSCR Assistant Professor Emory University School of Medicine Atlanta, GA 1 Objectives 1. Distinguish the various stages in the natural history of chronic hepatitis
More informationHBV in HIV Forgotten but not Gone
Activity Code FA376 HBV in HIV Forgotten but not Gone Richard K. Sterling, MD, MSc VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Learning Objectives
More informationHepatitis B. ECHO November 29, Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University
Hepatitis B ECHO November 29, 2017 Joseph Ahn, MD, MS Associate Professor of Medicine Director of Hepatology Oregon Health & Science University Disclosures Advisory board Gilead Comments The speaker Joseph
More informationHBV Diagnosis and Treatment
HBV Diagnosis and Treatment Anna S. F. Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor, MI, USA
More informationManagement of Chronic Hepatitis B in Asian Americans
Management of Chronic Hepatitis B in Asian Americans Myron J Tong; UCLA, CA Calvin Q. Pan; Mount Sinai, NY Hie-Won Hann; Thomas Jefferson, PA Kris V. Kowdley; Virginia Mason, WA Steven Huy B Han; UCLA,
More informationHepatitis B Treatment Pearls. Agenda
Hepatitis B Treatment Pearls Fredric D. Gordon, MD Vice Chair Dept. of Transplantation and Hepatobiliary Diseases Lahey Hospital & Medical Center Associate Professor of Medicine Tufts Medical School Boston,
More informationCURRENT TREATMENT. Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
CURRENT TREATMENT OF HBV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia CHRONIC HBV INFECTION DEMOGRAPHICS IN THE USA Estimated
More informationHepatitis B Diagnosis and Management. Marion Peters University of California San Francisco
Hepatitis B Diagnosis and Management Marion Peters University of California San Francisco COI Spouse works for Hoffmann-La Roche HBV is a life long, dynamic disease Changes over time Risk of end stage
More informationNH2 N N N O N O O P O O O O O
N N NH 2 N N O O P O O O O O O James Watson and Francis Crick Double Helix 1953 Baruch Blumberg, MD, PhD 1925-2011 Australia Antigen 1965 Hepatitis B Virus (HBV) Hepadnaviridae member that primarily infects
More informationHBV/HCV COINFECTIONS IN PATIENTS WITH HIV. Dr Reena Harania MBBS, MRCP, MSc Infectious Disease
HBV/HCV COINFECTIONS IN PATIENTS WITH HIV Dr Reena Harania MBBS, MRCP, MSc Infectious Disease Adults and children estimated to be living with HIV as of end 2005 North America 1.2 million [650 000 1.8 million]
More informationHepatitis B Update. Jorge L. Herrera, M.D. University of South Alabama Mobile, AL. Gastroenterology
Hepatitis B Update Jorge L. Herrera, M.D. University of South Alabama Mobile, AL Deciding Who to Treat Is hepatitis B a viral disease or a liver disease? Importance of HBV-DNA Levels in the Natural History
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis B José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HBV INFECTION
More informationViral Hepatitis. Dr Melissa Haines Gastroenterologist Waikato Hospital
Viral Hepatitis Dr Melissa Haines Gastroenterologist Waikato Hospital Viral Hepatitis HAV HBV HCV HDV HEV Other viral: CMV, EBV, HSV Unknown Hepatitis A Hepatitis A Transmitted via the faecal-oral route
More informationConsiderations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection
Considerations for Antiretroviral Use in Patients with Hepatitis B Virus & Human Immunodeficiency Syndrome Coinfection Mahnaz Arian, MD Assistant Professor in infectious Disease Mashhad university of Medical
More informationCornerstones of Hepatitis B: Past, Present and Future
Cornerstones of Hepatitis B: Past, Present and Future Professor Man-Fung Yuen Queen Mary Hospital The University of Hong Kong Hong Kong 1 Outline Past Natural history studies Development of HBV-related
More informationHBV NATURAL HISTORY. Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia
HBV NATURAL HISTORY AND MANAGMENT Mitchell L. Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, Virginia IVer Liver Institute of Virginia Education,
More informationChronic Hepatitis B Infection
Chronic Hepatitis B Infection Mohssen Nassiri Toosi, MD Imam Khomeinin Hospital Tehran University of Medical Sciences Chronic Hepatitis B Infection Virus : HBs Ag Positive Host Liver Health Chronic Hepatitis
More informationHepatitis B. Epidemiology and Natural History and Implications for Treatment
Hepatitis B Epidemiology and Natural History and Implications for Treatment Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco
More informationHepatitis B Case Studies
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Hepatitis B Case Studies Nina Kim, MD MSc Associate Professor of Medicine University of Washington Harborview Madison Clinic and Hepatitis & Liver Clinic No
More informationMarch 29, :15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D
March 29, 2017 12:15 PM 1:15 PM San Diego, CA Convention Center Ballroom 20D Provided by #IM2017 This lunch symposium is not part of the official Internal Medicine Meeting 2017 Education Program. #IM2017
More informationThe Impact of HBV Therapy on Fibrosis and Cirrhosis
The Impact of HBV Therapy on Fibrosis and Cirrhosis Jordan J. Feld, MD, MPH Associate Professor of Medicine University of Toronto Hepatologist Toronto Centre for Liver Disease Sandra Rotman Centre for
More informationNatural History of Chronic Hepatitis B
Natural History of Chronic Hepatitis B Anna SF Lok, MD Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research University of Michigan Ann Arbor,
More informationHepatitis B screening and surveillance in primary care
Hepatitis B screening and surveillance in primary care Catherine Stedman Associate Professor of Medicine, University of Otago, Christchurch Gastroenterology Department, Christchurch Hospital Disclosures
More informationBasics of hepatitis B diagnostics. Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology
Basics of hepatitis B diagnostics Dr Emma Page MRCP MD(Res) Locum Consultant Sexual Health & Virology Basics of hepatitis B diagnostics Background Epidemiology Morphology Life-cycle Diagnostic markers
More informationDr David Rowbotham NHS. The Leeds Teaching Hospitals. NHS Trust
Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust NHS Nurses Update June 2010 Chronic Hepatitis HBV / HCV David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology
More informationARTICLE IN PRESS. A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:xxx REVIEW A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: An Update EMMET B. KEEFFE,* DOUGLAS T. DIETERICH,
More informationThe natural course of chronic HBV infection can be divided into four, which are not always continuous.
HEPATITIS B Hepatitis B is a major global health problem. The WHO reports that there are 350 million carriers worldwide. This disease is the leading cause of liver cancer in the world and frequently leads
More informationChoice of Oral Drug for Hepatitis B: Status Asokananda Konar
Choice of Oral Drug for Hepatitis B: Status 2011 Asokananda Konar Chronic hepatitis B (CHB) is a global public health challenge with an estimated 350 to 400 million people with chronic HBV infection, despite
More informationManagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance
anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance / 김강모 연수강좌 anagement of chronic hepatitis B : recent advance in the treatment of antiviral resistance 김강모 울산대학교의과대학서울아산병원소화기내과
More informationViral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg
Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic
More informationViral hepatitis and Hepatocellular Carcinoma
Viral hepatitis and Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationNatural History of HBV Infection
Natural History of HBV Infection Joseph JY Sung MD PhD Institute of Digestive Disease Department of Medicine & Therapeutics Prince of Wales Hospital The Chinese University of Hong Kong HBV Infection 2
More informationOutline. Updates in the Clinical Management of Hepatitis B and C. Who should be screened for HBV? Chronic Hepatitis B 10/7/2018
Outline Updates in the Clinical Management of Hepatitis B and C Jennifer C. Lai, MD, MBA Transplant Hepatologist Associate Professor of Medicine In Residence University of California, San Francisco Initial
More informationManagement of Hepatitis B - Information for primary care providers
Management of Hepatitis B - Information for primary care providers July 2018 Chronic hepatitis B (CHB) is often a lifelong condition. Not everyone infected needs anti-viral therapy. This document outlines
More information2/12/2018. David M. Fettig, M.D. Birmingham Gastroenterology Associates. Outline basics of Hepatitis B. Phases of Chronic Hepatitis B
David M. Fettig, M.D. Birmingham Gastroenterology Associates Outline basics of Hepatitis B Phases of Chronic Hepatitis B Evaluation of Chronic Hepatitis B Treatment of Chronic Hepatitis B Special Populations
More informationAn Update HBV Treatment
An Update HBV Treatment Epidemiology Natural history Treatment Daryl T.-Y. Lau, MD, MPH Associate Professor of Medicine Director of Translational Liver Research Division of Gastroenterology BIDMC, Harvard
More informationGAZETTE COMMON GROUND. CHB: A significant and prevalent disease in the US and worldwide. Inside. Screening, diagnosis, and evaluation
VOL III/III COMMON GROUND GAZETTE Inside CASE 1: Screening, diagnosis, and evaluation P. 1 CASE 2: Initiating treatment P. 4 CASE 3: Managing antiviral resistance P. 5 CASE 4: Achieving the maximum effect
More informationHEPATITIS B MANAGEMENT
HEPATITIS B MANAGEMENT Background Chronic Hepatitis B Virus (HBV) infection had an estimated prevalence in Australia of 0.7-0.8% in 2002 (1). Prevalence is highest in people born in much of Asia and Africa
More informationHBV/HIV Co-infection in sub-saharan Africa CWN Spearman
HBV/HIV Co-infection in sub-saharan Africa CWN Spearman Division of Hepatology Department of Medicine Groote Schuur Hospital & University of Cape Town HIV/HBV Co-infection Outline of Talk Epidemiology
More informationPrimary Care for Hepatitis B and C:
Primary Care for Hepatitis B and C: Clinical Tools for Efficient Management Estimated 17 Million Persons With HCV Infection Worldwide 3-4 million newly infected each yr worldwide Advances in Internal Medicine
More informationHepatitis B: A Preventable Cause of Liver Cancer. Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016
Hepatitis B: A Preventable Cause of Liver Cancer Saira Khaderi MD, MPH Assistant Professor of Surgery Associate Director, Project ECHO June 17, 2016 Overview Epidemiology HBV and cancer Screening, Diagnosis
More informationHepatitis B. What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013
Hepatitis B What's the impact on the risk? Dr Himanshu Bhatia, Asia Chief Medical Officer ALUCA, Brisbane, Sept 2013 Some quick facts about Hepatitis B Worldwide: 350-400 Million are chronic infections
More informationMaitines septiembre de 2011 Francisco Jorquera Plaza
Bringing Into Focus: A Practical Guide to Using Virologic and Serologic Tests in the Management of Hepatitis B Maitines septiembre de 2011 Francisco Jorquera Plaza 2.000 millones de personas infectadas
More informationConsensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition
Consensus AASLD-EASL HBV Treatment Endpoint and HBV Cure Definition Anna S. Lok, MD, DSc Alice Lohrman Andrews Professor in Hepatology Director of Clinical Hepatology Assistant Dean for Clinical Research
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationManagement of Hepatitis B & HIV Coinfection: A Clinical Update. Douglas G. Fish, MD Albany Medical College Cali, Colombia March 14, 2008
Management of Hepatitis B & HIV Coinfection: A Clinical Update Douglas G. Fish, MD Albany Medical College Cali, Colombia March 14, 2008 In patients with HIV/HBV co-infection who are HBcoreAb(IgG + IgM)
More informationHepatitis B in Africa: Epidemiology, Pathophysiology and Challenges
Gilead-sponsored symposium at the 11th INTEREST Workshop 2017 Hepatitis B in Africa: Epidemiology, Pathophysiology and Challenges Ponsiano Ocama Department of Medicine Makerere University College of Health
More informationHepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
Hepatitis B Virus therapy Maria Buti Hospital Universitario Valle Hebron Barcelona Spain Disclosures Advisor: AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp &
More informationUpdate on HIV-HCV Epidemiology and Natural History
Update on HIV-HCV Epidemiology and Natural History Jennifer Price, MD Assistant Clinical Professor of Medicine University of California, San Francisco Learning Objectives Upon completion of this presentation,
More informationHepatocellular Carcinoma: Can We Slow the Rising Incidence?
Hepatocellular Carcinoma: Can We Slow the Rising Incidence? K.Rajender Reddy M.D. Professor of Medicine Director of Hepatology Medical Director of Liver Transplantation University of Pennsylvania Outline
More informationViral Hepatitis Diagnosis and Management
Viral Hepatitis Diagnosis and Management CLINICAL BACKGROUND Viral hepatitis is a relatively common disease (25 per 100,000 individuals in the United States) caused by a diverse group of hepatotropic agents
More informationWho to Treat? Consider biopsy Treat. > 2 ULN Treat Treat Treat Treat CIRRHOTIC PATIENTS Compensated Treat HBV DNA detectable treat
Who to Treat? Parameter AASLD US Algorithm EASL APASL HBV DNA CRITERIA HBeAg+ >, IU/mL > 2, IU/mL > 2, IU/mL >, IU/mL HBeAg- > 2, IU/mL > 2, IU/mL > 2, IU/mL > 2, IU/mL ALT CRITERIA PNALT 1-2 ULN Monitor
More informationGish RG and AC Gadano. J Vir Hep
Treatment in Hepatitis B and C There are options! Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Hepatitis B Virus Epidemiology and natural history 400
More informationDILEMMAS IN THE MANAGEMENT OF CO-INFECTION IN HIV-INFECTED CHILDREN
DILEMMAS IN THE MANAGEMENT OF CO-INFECTION IN HIV-INFECTED CHILDREN E NEL DEPARTMENT OF PAEDIATRICS AND CHILD HEALTH, FHS, STELLENBOSCH UNIVERSITY, SOUTH AFRICA HIV/HBV CO-INFECTION Prevalence of co-infection:
More informationOptimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy. Watcharasak Chotiyaputta
Optimized HBV Treatment Through Baseline and on-treatment Predictor Oral Antiviral Therapy Watcharasak Chotiyaputta Progression of Liver Disease Goal of HBV Treatment: prevention the development of cirrhosis
More informationEmerging Challenges In Primary Care: Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, and How 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor
More informationHIV-HBV coinfection: Issues with treatment in 2018
HIV-HBV coinfection: Issues with treatment in 2018 Pr Karine Lacombe, INSERM UMR-S1136, IPLESP Infectious Diseases Dpt, St Antoine, AP-HP Sorbonne Université, Paris, France Global epidemiology Same routes
More informationNorth Africa) The prevalence of CHB varies widely across EMEA (Europe, Middle East & 8% High 2 8% Intermediate <2% Low
The prevalence of CHB varies widely across EMEA (Europe, Middle East & North Africa) 8% High 2 8% Intermediate
More informationHBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But
HBeAg-positve chronic hepatts B: Why do I treat my patent with a NA? Maria But Hospital Universitario Valle Hebron and Ciberehd del Insttuto Carlos III. Barcelona. Spain Disclosures Advisory board of,
More informationBritish HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2
British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2 Systematic literature search 2.1 Questions and PICO criteria Data bases: Medline,
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationEmerging Challenges In Primary Care: 2015
Emerging Challenges In Primary Care: 2015 Chronic Hepatitis B: Guidelines for Screening, Clinical Management, Whether to Follow or Treat, 1 Faculty Christopher O'Brien, MD, AGAF, FRCMI Professor of Clinical
More informationHepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals
Hepatitis C & HIV Coinfection and Brief Advances on Hepatitis B & HIV: The Evidence and New Proposals Douglas G. Fish, MD Albany Medical College April 3, 2009 Cali Colombia Objectives HCV Epidemiology
More informationHepatitis B Virus. Taylor Page PharmD Candidate 2019 February 1, 2019
Hepatitis B Virus Taylor Page PharmD Candidate 2019 February 1, 2019 Epidemiology 3218 cases of acute HBV reported in 2016 847,000 non-institutionalized persons living with chronic HBV in 2011-2012 Viral
More informationEASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection European Association for the Study of the Liver Introduction Our understanding of the natural history of hepatitis B
More informationHepatitis B infection
Hepatitis B infection Kenneth Kabagambe Executive Director The National Organization for People Living with Hepatitis B (NOPLHB Uganda General introduction: Viral hepatitis in Uganda Viruses that affect
More informationBible Class: Hepatitis B Virus Infection
Bible Class: Hepatitis B Virus Infection Nasser Semmo UVCM, Hepatology What is the HBV prevalence? 2 Hepatitis B Worldwide approx. 350 Mio. chronically infected with HBV Approx. 40% of the world population:
More informationClinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL
Clinical Management of Hepatitis B WAN-CHENG CHOW DEPARTMENT OF GASTROENTEROLOGY & HEPATOLOGY SINGAPORE GENERAL HOSPITAL The World Health Organisation recent initiatives on HBV infection Launching of the
More informationOur better understanding of the natural
TREATMENT OF CHRONIC HEPATITIS B: MASTERING THE BASICS ON A COMPLEX TOPIC Ke-Qin Hu, MD* ABSTRACT The availability of newer antiviral agents, as well as comprehensive treatment recommendations, has equipped
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationTreatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia
Treatment as a form of liver cancer prevention The clinical efficacy and cost effectiveness of treatment across Asia Prof. Henry LY Chan Head, Division of Gastroenterology and Hepatology Director, Institute
More informationHepatitis B: An Update COPYRIGHT
Hepatitis B: An Update Sanjiv Chopra, M.D. Professor of Medicine Harvard Medical School James Tullis Firm Chief Department of Medicine Beth Israel Deaconess Medical Center A Tale of Serendipity Baruch
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationMANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT. Professor Salimur Rahman
MANAGEMENT OF HBV & HCV INFECTION---SIMILARITIES & DISSIMILARITIES---PAST AND PRESENT Professor Salimur Rahman Department of Hepatology, BSMMU President, Association for the study of the liver, Dhaka,
More informationNUCs for Chronic Hepatitis B. Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona.
NUCs for Chronic Hepatitis B Rafael Esteban Hospital Universitario Valle Hebron and Ciberehd del Instituto Carlos III. Barcelona. Spain Disclosures Advisory board of, and/or, received speaker fee from
More informationHepatitis Delta. Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain
Hepatitis Delta Vicente Soriano Infectious Diseases Unit La Paz University Hospital & IdiPAZ Madrid, Spain Disclosures Member of speaker bureau and advisory board for: Roche, Boehringer, Gilead, Viiv,
More informationS401- Updates in the Treatments of Hepatitis B & C
S401- Updates in the Treatments of Hepatitis B & C Ruben Gonzalez-Vallina, MD Director of Gastroenterology Outpatient Initiatives Miami Children s Hospital Miami, Florida Disclosure of Relevant Relationship
More informationA Message to Presenters
A Message to Presenters As a healthcare professional speaking on behalf of Bristol-Myers Squibb (BMS), any presentation you make on our behalf must be consistent with the current FDA-approved product labeling
More informationIN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST
IN THE NAME OF GOD AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL D r. MANIJE DEZFULI INFECTIOUS DISEASES SPECIALIST Acute Viral Hepatitis The Anatomy of the Liver Hepatic Physiology Liver: Largest solid organ
More informationHepatitis B and D Update on clinical aspects
Hepatitis B and D Update on clinical aspects B. Müllhaupt Gastroenterology and Hepatology Swiss Transplant and HPB-Center University Hospital Zurich beat.muellhaupt@usz.ch B.M. 11.11.17 Hepatitis Strategy
More informationESCMID Online Lecture Library. by author
Pro-Con: To stop or not to stop hepatitis B treatment? To Stop HBV Treatment Resat Ozaras, MD, Professor Istanbul University, Cerrahpasa Medical School, Infection Dept. HBV Therapy Nucleos(t)ide analogues
More informationScottish Medicines Consortium
Scottish Medicines Consortium tenofovir disoproxil (as fumarate), 245 mg film-coated tablet (Viread ) No. (479/08) Gilead Sciences 06 June 2008 The Scottish Medicines Consortium has completed its assessment
More informationMedInform. HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Original Article
DOI: 10.18044/Medinform.201852.897 ISSUE 3, 2018 HBV DNA loss in Bulgarian patients on NUC therapy. Speed related factors. (NUC related speed of HBV DNA loss in Bulgaria) Donika Krasteva, Radosveta Tomova,
More informationViral Hepatitis And Liver Transplantation
Viral Hepatitis And Liver Transplantation Dr.Zeki KARASU Ege University Medical School Dep. Gastroenterology Hepatitis B 3-7 10 % HBV infection in liver transplant recipients, in western countries. 120
More informationA tale of two patients
15 th Annual Resistance and Antiviral Therapy Meeting Dr Sanjay Bhagani Royal Free Hospital, London Thursday 29 September 2011, Royal College of Physicians, London A tale of two patients Sanjay Bhagani
More informationViral hepatitis Prevention Board. Clinical aspects of hepatitis B
Viral hepatitis Prevention Board Clinical aspects of hepatitis B Natural History and serological markers acute and chronic hepatitis B Acute hepatitis B Immune response Immunological tolerance Resolution
More informationWorld Health Organization. Western Pacific Region
Standard modules for HBV 1 HBV Module 1 Hepatitis B serological markers and virology 2 Acute hepatitis HAV HBV HCV HDV HEV Case fatality Case fatality Uncommon increases with increases with age age Superinfection
More informationCommunity/GP based screening & management of HBV & HCV
Community/GP based screening & management of HBV & HCV Catherine Stedman Department of Gastroenterology, Christchurch Hospital and University of Otago, Christchurch Disclosures I have the following financial
More informationThe ABCs of Viral Hepatitis Diagnosis. Ila Singh, M.D., Ph.D. P & S Viral Hepatitis. Hepatitis A, B, C, D, E and G viruses
The ABCs of Viral Hepatitis Diagnosis Ila Singh, M.D., Ph.D. P & S 14-453 is132@columbia.edu Viral Hepatitis Hepatotropic viruses Hepatitis A, B, C, D, E and G viruses Generalized infection plus infection
More informationcoinfected patients predicts HBsAg clearance during long term exposure to tenofovir
Measurement of serum HBsAg in HIV/HBV coinfected patients predicts HBsAg clearance during long term exposure to tenofovir Zulema Plaza 1, Antonio Aguilera 2, Alvaro Mena 3, Luz Martín-Carbonero 1, Eugenia
More informationChronic hepatitis B: diagnosis, monitoring and management
PRESCRIBING IN PRACTICE n Chronic hepatitis B: diagnosis, monitoring and management Ben Hudson MRCP and Peter Collins MD, FRCP Hepatitis B is a blood-borne DNA virus and chronic disease is defined as failure
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Centre for Clinical Practice SCOPE Clinical guideline title: Hepatitis B (chronic): diagnosis and management of chronic hepatitis B in children, young
More informationViral Hepatitis. Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP
Viral Hepatitis Dr. Abdulwahhab S. Abdullah CABM, FICMS-G&H PROF. DR. SABEHA ALBAYATI CABM,FRCP Viral hepatitis Viral hepatitis must be considered in any patient presenting with hepatitis on LFTs (high
More informationTreatment Op+ons for Chronic Hepa++s B. Judith Feinberg, MD Project ECHO Jan. 19, 2017
Treatment Op+ons for Chronic Hepa++s B Judith Feinberg, MD Project ECHO Jan. 19, 2017 Treatment of Chronic Hepatitis B can be prevented by vaccinacon (part of infant series since 1992-3) goal of drug therapy
More informationEvidence Synthesis Number 110
Evidence Synthesis Number 110 Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: Systematic Review to Update the 2004 U.S. Preventive Services Task Force Recommendation Prepared
More informationIs there a need for combination therapy? No. Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain
Is there a need for combination therapy? No Maria Buti Hospital General Universitario Valle Hebron Barcelona. Spain No, No and No EASL Update HBV Guidelines 2012 The most potent drugs with the optimal
More informationTenofovir as a drug of choice for the chronic hepatitis B treatment
EASL endorsed conference White Nights of Hepatology 2013 Symposium Perspectives of chronic viral hepatitis B and C treatment June 6-7 Saint-Petersburg Tenofovir as a drug of choice for the chronic hepatitis
More informationESCMID Online Lecture Library. by author
Hepatitis B virus and solid organ transplantation Prof. Hakan Leblebicioglu Department of Clinical Microbiology and Infectious Diseases Ondokuz Mayis University, Samsun, Turkey Conflict of interest Outline
More information